Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03909334 | Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | PHASE2 | ACTIVE NOT_RECRUITING | 160 | — | — | Jul 25, 2019 | Jan 1, 2027 | Apr 17, 2026 | 12 | United States |
Progression free survival (PFS) time will be calculated from the date of randomization to disease progression or death from any cause, whichever occurs the first.
| Arm | Type | Description |
|---|---|---|
| Arm A (Osimertinib and Ramucirumab) | ACTIVE_COMPARATOR | Osimertinib and Ramucirumab |
| Arm B (Osimertinib) | ACTIVE_COMPARATOR | Osimertinib |
| Name | Type | Description |
|---|---|---|
| Osimertinib | DRUG | Osimertinib 80 mg orally on Day 1 |
| Ramucirumab | DRUG | Ramucirumab 10 mg/kg intravenously (IV) over 60 minutes for first infusion and if tolerated subsequent infusions may be over 30 minutes |
Inclusion Criteria: * Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. * Age ≥ 18 years at the time of consent. * Histologically or cytological...